People: Santarus Inc (SNTS.O)

Summary

Name	Age	Since	Current Position
David Hale		2004	Independent Chairman of the Board
Gerald Proehl	53	2002	President, Chief Executive Officer, Director
Debra Crawford	54	2003	Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Wendell Wierenga	65	2011	Executive Vice President - Research and Development
Carey Fox	43	2008	Senior Vice President, General Counsel
Julie DeMeules	59	2006	Senior Vice President - Human Resources
E. David Ballard	56	2011	Senior Vice President - Medical Affairs and Pharmacovigilance
Maria Bedoya-Toro	60	2011	Senior Vice President - Regulatory Affairs and Quality Assurance
William Denby	55	2002	Senior Vice President - Commercial Operations
Warren Hall	59	2003	Senior Vice President - Manufacturing and Product Development
Michael Step	52	2005	Senior Vice President - Corporate Development
Mark Totoritis	57	2011	Senior Vice President - Clinical Research
Martha Hough	58	2005	Vice President - Finance and Investor Relations
Teri Chuppe	49	2011	Vice President, Corporate Controller
Blake Boland	51	2004	Vice President - Sales
Thomas Joyce	52	2004	Vice President - Marketing and National Accounts
Jonathan Hee	53	2004	Vice President - Commercilal Affairs
Alessandro Della Cha	50	2012	Director
Daniel Burgess	50	2004	Independent Director
Michael Carter	75	2005	Independent Director
Michael Herman	70	2003	Independent Director
Ted Love	53	2005	Independent Director
Kent Snyder	58	2004	Independent Director

» Insider Trading

Biographies

Name	Description
David Hale	Mr. David F. Hale is Independent Chairman of the Board of Santarus Inc., since February 2004. He has served as a member of our board of directors since June 2000. Since May 2006, Mr. Hale has served as Chairman and Chief Executive Officer of Hale BioPharma Ventures, LLC. In March 2011, Mr. Hale was appointed Executive Chairman of Biocept, Inc. Mr. Hale is a co-founder of Somaxon Pharmaceuticals, Inc. and currently serves as the Non-Executive Chairman of the board of directors. Prior to this position, he served as Chairman of the board of directors from August 2003 to December 2007, interim Chief Executive Officer from January 2008 to August 2008, and Executive Chairman from December 2007 to June 2009. From October 2000 to May 2006, Mr. Hale served as President and Chief Executive Officer of CancerVax Corporation. From December 2000 to May 2006, Mr. Hale was also a director of CancerVax Corp. In May 2006, CancerVax Corporation merged with Micromet AG to form Micromet, Inc., a biopharmaceutical company, of which Mr. Hale was Chairman until Micromet was acquired by Amgen Inc. in March 2012. Prior to joining CancerVax Corporation, Mr. Hale served as President and Chief Executive Officer and a director of Women First HealthCare, Inc., from January 1998 to May 2000. From May 1987 to February 1997, he served as Chairman, President and Chief Executive Officer of Gensia Inc. From February 1987 to September 1994, Mr. Hale served as Chairman of Viagene, Inc. Mr. Hale joined Hybritech, Incorporated, in 1982 and served as Chief Operating Officer, President, Chief Executive Officer and a director until May 1987. Mr. Hale served as a director of Metabasis Therapeutics, Inc. from April 1997 to August 2006, Chairman of the board of directors from August 2006 to September 2009, Executive Chairman from September 2009 to January 2010 and acting Chief Executive Officer from October 2009 to January 2010. Mr. Hale holds a B.A. in biology and chemistry from Jacksonville State University.
Gerald Proehl	Mr. Gerald T. Proehl is President, Chief Executive Officer, Director of Santarus Inc. Mr. Proehl has served in these capacities since January 2002. From March 2000 through December 2001, Mr. Proehl was Company's President and Chief Operating Officer. From April 1999 to March 2000, Mr. Proehl was Company's Vice President, Marketing and Business Development. Prior to joining Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc., a global pharmaceutical company, for 14 years, where he served in various capacities in multiple therapeutic areas including gastrointestinal, cardiovascular, wound care and central nervous system, and from March 1997 to April 1999 served as Vice President of Global Marketing. While at Hoechst Marion Roussel, Mr. Proehl was responsible for the marketing of gastrointestinal products Carafate® and Pentasa®, among products in several other therapeutic areas. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst College.
Debra Crawford	Ms. Debra P. Crawford is Chief Financial Officer, Senior Vice President, Treasurer, Secretary of Santarus Inc. Ms. Crawford joined Santarus in November 2000 as Vice President, Chief Financial Officer, Treasurer and Secretary and was promoted to her current position in December 2003. Prior to joining Santarus, Ms. Crawford served as Vice President, Chief Financial Officer and Treasurer from July 1998 to May 2000 for Women First HealthCare, Inc., a specialty healthcare company. Ms. Crawford was also Assistant Secretary of Women First from July 1998 to February 1999 and Secretary from March 1999 to May 2000. From May 2000 to October 2000 and from March 1997 to August 1998, Ms. Crawford was self-employed and provided financial consulting services in the area of corporate development and in the capacity of acting chief financial officer. Ms. Crawford also served as Chief Financial Officer, Vice President of Finance and Administration and Treasurer of IVAC Holdings, Inc. from January 1996 to December 1996 and of IVAC Medical Systems, Inc., a medical device company, from January 1995 to December 1996. From September 1981 to December 1994, Ms. Crawford served in various financial positions within companies of the medical device division of Eli Lilly & Company. Ms. Crawford holds a B.S. in business administration from San Diego State University.
Wendell Wierenga	Dr. Wendell Wierenga, Ph.D., is Executive Vice President - Research and Development of Santarus Inc., since June 2011. From 2007 to 2011 Dr. Wierenga served as Executive Vice President, Research and Development of privately held Ambit Biosciences Corporation, where he was responsible for all research and drug development activities including clinical, regulatory affairs and manufacturing. From 2003 to 2007, he was Executive Vice President, Research and Development of Neurocrine Biosciences, Inc., where he led all research and drug development activities. From 2000 to 2003, Dr. Wierenga served as the Chief Executive Officer of biotechnology company Syrrx, Inc., a spinout from the Genomics Institute of the Novartis Research Foundation. Dr. Wierenga served 10 years with Warner-Lambert, joining as Senior Vice President of Research for Parke-Davis, the company’s pharmaceutical research division, and promoted in 1999 to Senior Vice President, Worldwide Pharmaceutical Sciences, Technologies and Development. He began his career in 1974 as a research scientist at The Upjohn Company and was Director of Cancer and Viral Diseases Research when he left in 1990. Dr. Wierenga holds a B.A. in chemistry from Hope College and a Ph.D. in chemistry from Stanford University.
Carey Fox	Ms. Carey J. Fox, J.D. is Senior Vice President, General Counsel of Santarus Inc. Ms. Fox joined Santarus as Senior Director, Legal Affairs in March 2002, was promoted to Vice President, Legal Affairs in May 2004, was promoted to Vice President, General Counsel in March 2006 and was promoted to her current position in September 2008. Prior to joining Santarus, Ms. Fox served as Director, Legal Affairs for Elan Pharmaceuticals, Inc., a pharmaceutical company, from January 2002 to March 2002. Prior to joining Elan, Ms. Fox was associated with the law firm of Brobeck, Phleger & Harrison LLP from May 1998 to December 2001 and with the law firm of Fennemore Craig from January 1996 to May 1998, where she represented a variety of clients in general corporate and securities law matters. Ms. Fox is a member of the State Bar of California and holds a B.A. in social ecology from the University of California, Irvine and a J.D. from Arizona State University.
Julie DeMeules	Ms. Julie A. DeMeules is Senior Vice President - Human Resources of Santarus Inc. Ms. DeMeules joined Santarus in January 2004 as Vice President, Human Resources and was promoted to her current position in February 2006. From January 2000 to November 2003, Ms. DeMeules served as Vice President, Human Resources at Quidel Corporation, a manufacturer and distributor of medical diagnostic products. From February 1991 to January 2000, Ms. DeMeules was employed with Advanced Tissue Sciences, a biotechnology company, most recently serving as Vice President, Human Resources. Prior to joining Advanced Tissue Sciences, Ms. DeMeules served as Director of Human Resources at Square D Corporation, a provider of electrical products, from June 1990 to February 1991. Prior to joining Square D Corporation, Ms. DeMeules served for several years as Vice President of Human Resources of Signet Armorlite, Inc., a manufacturer and distributor of ophthalmic lenses and supplies. Ms. DeMeules holds a B.A. in business administration from the University of San Diego and an M.B.A. from San Diego State University.
E. David Ballard	Dr. E. David Ballard II, M.D., is Senior Vice President - Medical Affairs and Pharmacovigilance of Santarus Inc. Dr. Ballard joined Santarus in March 2004 as Vice President, Clinical Research, was appointed Vice President, Medical Affairs in September 2005, was promoted to Vice President, Clinical Research and Medical Affairs in March 2006, was promoted to Senior Vice President, Clinical Research and Medical Affairs in September 2008 and appointed to his current position in February 2011. From March 2000 to February 2004, Dr. Ballard served in various positions at TAP Pharmaceutical Products Inc., a pharmaceutical company, most recently serving as Therapeutic Area Head, Gastroenterology and Internal Medicine. From July 1997 to March 2000, Dr. Ballard was a Medical Director at Abbott Laboratories, a pharmaceutical company. Dr. Ballard holds a B.S. in biology from Morehouse College and an M.D. from the Medical College of Ohio. Dr. Ballard is also certified as a gastroenterologist by the American Board of Internal Medicine.
Maria Bedoya-Toro	Dr. Maria Bedoya-Toro, Ph.D., is Senior Vice President - Regulatory Affairs and Quality Assurance of Santarus Inc., since February 2011. Dr. Bedoya-Toro joined Santarus in May 2007 as Vice President, Regulatory Affairs and Quality Assurance, and was promoted to her current position in February 2011. She previously served as Senior Director Regulatory Affairs at Eisai Medical Research Inc. from November 2006 to May 2007, moving to Eisai from Ligand Pharmaceuticals, Inc. when Ligand divested their oncology products to Eisai in November 2006. Dr. Bedoya-Toro worked as Senior Director Global Regulatory Affairs and Compliance at Ligand from 2003 to 2006. From 2000 to 2003 she served as Director Global Regulatory Affairs at Baxter Hyland Immuno. From 1998 to 2000 Dr. Bedoya-Toro worked at BASF Bioresearch Corporation as Director Regulatory Affairs/Quality, and from 1996 to 1998 she worked as Director Quality Assurance and Regulatory Compliance at Amylin Pharmaceuticals. From 1988 to 1996 Dr. Bedoya-Toro worked at Rhone-Poulenc Rorer in a number of increasingly responsible positions in regulatory compliance, quality assurance, quality control and compliance. Dr. Bedoya-Toro holds an M.B.A. from the University of Chicago and a Ph.D. in bio-analytical chemistry from Ohio University. In addition she has an M.A. in bio-analytical chemistry and a B.S. in chemistry from Western Michigan University.
William Denby	Mr. William C. Denby, III is Senior Vice President - Commercial Operations of Santarus Inc. Mr. Denby has held this position since he joined Santarus in February 2002. Prior to joining Santarus, from October 2001 to February 2002, Mr. Denby served as Senior Vice President of Commercial Operations of Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From June 1997 to October 2001, Mr. Denby served as Senior Vice President and Vice President of Sales and Marketing for Agouron. From January 1995 to June 1997, Mr. Denby served as Senior Director of Sales and Marketing and Senior Director, Commercial and Marketing Affairs for Agouron. Prior to that, Mr. Denby was at Marion Laboratories for 18 years, holding various positions in corporate finance, strategic planning, and sales and marketing. While at Marion Laboratories, Mr. Denby was responsible for promoting a diverse product line which included brands such as Cardizem®, Nicorette® and the duodenal ulcer drug Carafate, and he helped secure managed care formulary acceptance for these products. Mr. Denby holds a B.A. in English from the State University of New York at Fredonia and an M.B.A. from Rockhurst College.
Warren Hall	Mr. Warren E. Hall is Senior Vice President - Manufacturing and Product Development of Santarus Inc. Mr. Hall joined Santarus in July 2001 as Vice President, Manufacturing and Product Development and was promoted to his current position in December 2003. Prior to joining Santarus, Mr. Hall served as Senior Director of Development from July 2000 to July 2001 at Dura Pharmaceuticals, a specialty pharmaceutical company that was acquired by Elan Corporation, plc, a pharmaceutical company. Mr. Hall served as Senior Director of Program Management for the pulmonary group at Dura from February 1999 to July 2000, and as Senior Director of Manufacturing from July 1998 to February 1999. From November 1995 to June 1998, Mr. Hall served as Director of Manufacturing Operations at Cell Therapeutics, Inc., a cancer treatment company. Prior to Cell Therapeutics, Mr. Hall was with Mallinckrodt, Inc., a pharmaceutical and specialty chemical company, for 17 years, serving in various capacities, most recently as Director of Worldwide Manufacturing. Mr. Hall holds a B.A. in chemistry and biology from Greenville College and an M.S. in organic chemistry from Southern Illinois University.
Michael Step	Mr. Michael D. Step is Senior Vice President - Corporate Development of Santarus Inc. Mr. Step has held this position since he joined Santarus in February 2005. Prior to joining Santarus, he served from August 2000 to February 2005 with Amylin Pharmaceuticals, Inc., a biopharmaceutical company, most recently as Vice President, Corporate Development. In this capacity, he was responsible for corporate development activities, including product licensing, strategic planning, and mergers and acquisitions evaluations. Prior to Amylin, he was Senior Director, Business Development at Dura Pharmaceuticals, Inc., a pharmaceutical company, from May 1998 to July 2000. In this position, his duties included licensing of marketed pharmaceutical products. Prior to that, he served in corporate development and strategic planning at Hoffmann-La Roche and sales and management roles at Roche Labs and Syntex Labs. Mr. Step holds a B.A. in political science from Vanderbilt University and an M.B.A. from the University of Southern California.
Mark Totoritis	Dr. Mark C. Totoritis, M.D., is Senior Vice President - Clinical Research of Santarus Inc. Dr. Totoritis joined Santarus in September 2010 as Senior Vice President, Biologics and was appointed to his current position in February 2011. From 2007 to September 2010, Dr. Totoritis was associated with Covella Pharmaceuticals, Inc., a start-up biotechnology company that he co-founded and for which he served as Chief Medical Officer until its acquisition by Santarus in September 2010. From 2003 to 2006 he was Vice President of Medical Research and Head of the Immunology/Rheumatology Therapeutics Group at Biogen Idec. Dr. Totoritis also worked as Head of the Autoimmune and Inflammatory Diseases Group at IDEC Pharmaceuticals from 1997 through its merger with Biogen in 2003, rising to the position of vice president. He played a key role in the development and approval for rheumatoid arthritis of Rituxan®, a biologic drug sold by Genentech and Biogen Idec and also approved for non-Hodgkin’s lymphoma. Dr. Totoritis worked at Advanced Tissue Sciences, Inc. from 1995 to 1997, where his efforts contributed to the approval of the company’s first bioengineered human tissue product for the treatment of burn wounds. Earlier in his career, while at Syntex Research/Roche Bioscience, Dr. Totoritis was a contributor to the development of CellCept® for use in patients undergoing solid organ transplantation. He holds an A.B. in human biology from Stanford University and an M.D. from Eastern Virginia Medical School. Dr. Totoritis is board certified in internal medicine and rheumatology by the American Board of Internal Medicine.
Martha Hough	Ms. Martha L. Hough is Vice President - Finance and Investor Relations of Santarus Inc. Ms. Hough has held this position since she joined Santarus in January 2005. From August 2002 to December 2004, and September 1998 to October 1999, Ms. Hough was a self-employed consultant to medical technology and pharmaceutical companies. From November 1999 to July 2002, Ms. Hough was Vice President, Business Development, and Chief Financial Officer of LMA North America, Inc., a profitable private medical device company. From 1987 to 1998, Ms. Hough worked in various finance, investor relations, and marketing positions at Gensia Sicor, Inc., serving as Vice President, Finance and Corporate Communications there from January 1995 to June 1998. Ms. Hough holds a B.S. in psychology from Colorado State University and an M.B.A. from the Tuck School of Business at Dartmouth College.
Teri Chuppe	Ms. Teri L. Chuppe is Vice President, Controller of Santarus Inc. Ms. Chuppe joined Santarus as Director, Finance and Controller in April 2001, was promoted to Senior Director, Finance and Controller in May 2004, was promoted to Executive Director, Finance and Controller in March 2006 and was promoted to her current position in April 2011. Prior to joining Santarus, Ms. Chuppe served as Director, Finance and Controller for Trega Biosciences, Inc., a biotechnology company, from July 2000 to April 2001 and served as Controller for Women First HealthCare, Inc., a specialty healthcare company, from November 1998 to July 2000. From August 1995 to November 1998, Ms. Chuppe served as Senior Accounting Manager for Amylin Pharmaceuticals, Inc., a specialty biopharmaceutical company, and from January 1989 to July 1995, she served in various financial positions for IVAC Corporation, a company within the medical device division of Eli Lilly & Company. From July 1985 to December 1988, Ms. Chuppe was with Arthur Andersen & Co. Ms. Chuppe holds a B.S. in business administration from San Diego State University.
Blake Boland	Mr. Blake A. Boland is Vice President - Sales of Santarus Inc. Mr. Boland joined Santarus in January 2004 as Director, National Sales and was promoted to his current position in July 2004. Prior to joining Santarus, Mr. Boland was with Aventis Pharmaceuticals, a global pharmaceutical company, for 16 years. From November 1998 to December 2003, Mr. Boland served as a Regional Sales Director, where he was responsible initially for building a new primary care sales organization in the western U.S. During his career with Aventis and predecessor companies, Mr. Boland held various positions in sales, marketing and sales management in such therapeutic areas as gastroenterology, cardiovascular, respiratory, diabetes and anti-infectives. Mr. Boland holds a B.A. in business administration from Graceland College and an M.B.A. from Rockhurst College.
Thomas Joyce	Mr. Thomas J. Joyce is Vice President - Marketing and National Accounts of Santarus Inc. Mr. Joyce has held this position since he joined Santarus in January 2004. From April 2002 to January 2004, Mr. Joyce served as Senior Director, Marketing at Neurocrine Biosciences, Inc., a drug discovery and development company. From July 1999 to March 2002, Mr. Joyce served as Senior Director, Global Marketing Planning of Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From September 1997 to June 1999 and from May 1996 to August 1997, Mr. Joyce served as Associate Director of Corporate Development and Senior Market Manager, respectively, of Agouron. Prior to joining Agouron, Mr. Joyce held various sales and sales management positions at Hoechst Marion Roussel. Mr. Joyce holds a B.A. in psychology from the University of Dayton.
Jonathan Hee	Mr. Jonathan M. Hee is Vice President - Commercilal Affairs of Santarus Inc. Mr. Hee has held this position since he joined Santarus in January 2004. From October 2000 to December 2003, Mr. Hee served as Vice President, Sales and Marketing Services at Agouron Pharmaceuticals, Inc., a provider of HIV and other specialty pharmaceutical products that was acquired by Pfizer Inc. From October 1996 to October 2000, Mr. Hee served as Director and Senior Director, Sales and Marketing Services for Agouron. Mr. Hee was a Senior Manager of Segment Marketing for Agouron from November 1995 to October 1996. Prior to joining Agouron, Mr. Hee was with Gensia Inc., a cardiovascular and multi-source injectable drug company, where he held various management roles including Associate Director positions in marketing and market planning. Mr. Hee holds a B.S. in chemical engineering from Stanford University and an M.B.A. from Harvard University.
Alessandro Della Cha	Mr. Alessandro E. Della Cha is Director of Santarus Inc., since April 10, 2012. Since 1997, Mr. Della Chà has been a senior partner of Studio Legale Edoardo Ricci e Associati, and has served as a co-managing director of the firm since 2003. He currently serves as a director of Cosmo Pharmaceuticals S.p.A. Mr. Della Chà holds a degree in law from the Università degli Studi di Milano and a Masters in European Commercial Law from the University of Leicester, England.
Daniel Burgess	Mr. Daniel D. Burgess is Independent Director of Santarus Inc., since July 2004. Since June 2011, Mr. Burgess has been President and Chief Executive Officer of Rempex Pharmaceuticals, Inc., a private biopharmaceutical company. Prior to that, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., a private biopharmaceutical company, which he joined in May 2007 and which was acquired by Aptalis Pharma Inc. in 2011. From August 1999 to May 2007, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden Pharmaceuticals, Inc., a pharmaceutical company. Mr. Burgess joined Harbor BioSciences from Nanogen Inc., a supplier of molecular diagnostic tests, where he served as Vice President and Chief Financial Officer. Prior to joining Nanogen in 1998, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited), formerly Gensia Inc., a specialty pharmaceutical company, and Gensia Automedics, Inc., a partially owned subsidiary of Gensia Sicor. He served as President and a director of Gensia Automedics, where he was responsible for all functional areas of this medical products company. In addition, he was Vice President and Chief Financial Officer of Gensia Sicor, where he was responsible for finance, investor relations, business development and other administrative functions. Prior to joining Gensia, Mr. Burgess held positions at Castle & Cooke, Inc. and Smith Barney, Harris Upham and Company. Mr. Burgess served as a director of Metabasis Therapeutics, Inc. from March 2004 until its acquisition by Ligand Pharmaceuticals Incorporated in January 2010. He holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.
Michael Carter	Dr. Michael G. Carter, M.B., Ch.B., F.R.C.P. (U.K.) , is Independent Director of Santarus Inc., since February 2005. Dr. Carter has been a venture partner at S.V. Life Sciences Advisers LLP since 1998. He retired from Zeneca, PLC, a publicly traded global pharmaceutical company, in 1998. Dr. Carter served Zeneca as International Medical Director from 1986 to 1989 and International Marketing Director from 1990 to 1995. From 1976 to 1984, Dr. Carter held several positions with Roche Products, Ltd., including head of Medical Development and Medical Affairs, and Director of the Pharmaceutical Division. Dr. Carter currently serves as a director of GTx, Inc., a men’s health biotechnology company, in the U.S. Since September 2009, he has been a member of the Strategic Advisory Board of Cowen Healthcare Royalty Fund. He is an elected fellow of the Royal Pharmaceutical Society, Faculty of Pharmaceutical Medicine, and of the Royal College of Physicians of Edinburgh. Dr. Carter holds a bachelor’s degree in pharmacy from London University (U.K.) and a medical degree from Sheffield University Medical School (U.K.).
Michael Herman	Mr. Michael E. Herman is Independent Director of Santarus Inc., since September 2003. From January 1992 to December 2000, Mr. Herman was President of the Kansas City Royals Baseball Club. From January 1990 to December 1999, he was Chairman of the Finance and Investment Committee of the Kauffman Foundation and was its President from January 1985 to December 1990. From October 1974 to December 1990, Mr. Herman was the Executive Vice President and Chief Financial Officer of Marion Laboratories. Mr. Herman is a director of Senomyx, Inc., a biotechnology company, and also is a Trustee of Rensselaer Polytechnic Institute and the University of Chicago Graduate School of Business. He also serves as a member of the board of directors of Vail Valley Foundation. Mr. Herman also previously served as a director of Cerner Corporation, Janus Capital, Eloquent, Inc. and Agouron Pharmaceuticals, Inc. Mr. Herman holds a B.S. in metallurgical engineering from Rensselaer Polytechnic Institute and an M.B.A. from the University of Chicago.
Ted Love	Dr. Ted W. Love, M.D. is Independent Director of Santarus Inc., since March 2005. Since February 2010 he has served as Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals, Inc., and in January 2011 he assumed responsibility for technical operations. In February 2012, Onyx Pharmaceuticals disclosed that Dr. Love would be retiring effective August 1, 2012 and that he would serve as a consultant following his retirement through December 31, 2012. He previously served as President and Chief Executive Officer of Nuvelo, Inc., a biopharmaceutical company, from March 2001 to January 2009, having been appointed President and Chief Operating Officer of Nuvelo in January 2001. He served as a director of Nuvelo starting in February 2001 and became Chairman of the board of directors in September 2005. He joined Nuvelo from Theravance, Inc. (formerly Advanced Medicine), a biopharmaceutical company, where he served as Senior Vice President of Development from February 1998 to January 2001. Prior to that, he spent six years at Genentech, Inc., a biotechnology company, holding a number of senior management positions in medical affairs and product development. Dr. Love currently serves on the board of directors of Affymax, Inc., Bio-Rad Laboratories, Inc. and the California Institute for Regenerative Medicine (CIRM) Independent Citizen’s Oversight Committee. Dr. Love also previously served on the board of directors of ARCA biopharma, Inc. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.
Kent Snyder	Mr. Kent Snyder is Independent Director of Santarus Inc., since September 2004. Since September 2009, Mr. Snyder has been the Chief Executive Officer and Chairman of Senomyx, Inc., a San Diego-based biotechnology company. From June 2003 to August 2009, Mr. Snyder was President and Chief Executive Officer and a director of Senomyx. In May 2008, Mr. Snyder assumed the role of Chairman of the board of directors of Senomyx. Prior to joining Senomyx, from October 2001 to June 2003, Mr. Snyder was retired. From July 1991 to October 2001, Mr. Snyder held various management positions with Agouron Pharmaceuticals, Inc., a Pfizer company, including President of Global Commercial Operations. Prior to holding the position of President of Global Commercial Operations, Mr. Snyder served as Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Rockhurst College.

Basic Compensation

Name	Fiscal Year Total
David Hale	--
Gerald Proehl	2,088,260
Debra Crawford	761,814
Wendell Wierenga	761,918
Carey Fox	751,470
Julie DeMeules	538,354
E. David Ballard	785,325
Maria Bedoya-Toro	--
William Denby	775,152
Warren Hall	562,851
Michael Step	728,954
Mark Totoritis	--
Martha Hough	--
Teri Chuppe	--
Blake Boland	--
Thomas Joyce	--
Jonathan Hee	--
Alessandro Della Cha	--
Daniel Burgess	--
Michael Carter	--
Michael Herman	--
Ted Love	--
Kent Snyder	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
David Hale	0	0
Gerald Proehl	1,019,548	3,321,667
Debra Crawford	405,923	1,045,880
Wendell Wierenga	0	0
Carey Fox	0	0
Julie DeMeules	0	0
E. David Ballard	0	0
Maria Bedoya-Toro	0	0
William Denby	268,589	598,293
Warren Hall	254,384	578,711
Michael Step	100,000	0
Mark Totoritis	0	0
Martha Hough	0	0
Teri Chuppe	0	0
Blake Boland	0	0
Thomas Joyce	0	0
Jonathan Hee	0	0
Alessandro Della Cha	0	0
Daniel Burgess	0	0
Michael Carter	0	0
Michael Herman	0	0
Ted Love	0	0
Kent Snyder	0	0

Insider Trading

Name	Shares Traded	Price
DELLA CHA ALESSANDRO	16,500	$21.33
COSMO TECHNOLOGIES LTD	4,887,500	$17.68
HERMAN MICHAEL E	30	$0.00
HERMAN MICHAEL E	25,000	$20.77
CRAWFORD DEBRA P	18,643	$19.27
CRAWFORD DEBRA P	18,643	$3.50
DE MEULES JULIE A	11,647	$5.25
DE MEULES JULIE A	15,165	$20.10
BEDOYA-TORO MARIA E	10,000	$20.53
BEDOYA-TORO MARIA E	5,668	$2.36
BEDOYA-TORO MARIA E	4,332	$1.18
FOX CAREY J	17,100	$20.86
FOX CAREY J	17,100	$1.18
STEP MICHAEL D	30,301	$1.18
STEP MICHAEL D	30,301	$18.74
PROEHL GERALD T	86,603	$18.73
PROEHL GERALD T	86,603	$0.88
HALL WARREN E	28,749	$18.89
HALL WARREN E	1,636	$3.50
HALL WARREN E	26,258	$3.50
BALLARD E DAVID II	9,000	$1.18
BALLARD E DAVID II	9,000	$18.45
DENBY WILLIAM C III	19,598	$3.50
DENBY WILLIAM C III	24,450	$17.90
BURGESS DANIEL D	8,000	$3.00

» Full list on Insider Trading

People: Santarus Inc (SNTS.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: